Company delivered ROE of 12.86% in year ending Mar 31, 2024 outperforming its 5 year avg. of 9.91%. (Source: Standalone Financials)
Fredun Pharmaceuticals Share Price
Fredun Pharmaceuticals ...
Fredun Pharma share price insights
Company witnessed QoQ revenue decline of 33.23%, which is lowest in the last 3 years. (Source: Standalone Financials)
Stock gave a 3 year return of 107.24% as compared to Nifty Smallcap 100 which gave a return of 91.39%. (as of last trading session)
Company has spent 3.91% of its operating revenues towards interest expenses and 3.58% towards employee cost in the year ending Mar 31, 2024. (Source: Standalone Financials)
Fredun Pharmaceuticals Ltd. share price moved down by -1.21% from its previous close of Rs 797.20. Fredun Pharmaceuticals Ltd. stock last traded price is 787.50
Share Price Value Today/Current/Last 787.50 Previous Day 797.20
Key Metrics
PE Ratio (x) | 21.33 | ||||||||||
EPS - TTM (₹) | 36.92 | ||||||||||
MCap (₹ Cr.) | 370.06 | ||||||||||
Sectoral MCap Rank | 103 | ||||||||||
PB Ratio (x) | 3.07 | ||||||||||
Div Yield (%) | 0.09 | ||||||||||
Face Value (₹) | 10.00 | ||||||||||
Beta Beta
| 0.09 | ||||||||||
VWAP (₹) | 787.30 | ||||||||||
52W H/L (₹) |
Fredun Pharma Share Price Returns
1 Day | -1.21% |
1 Week | -1.06% |
1 Month | -9.99% |
3 Months | -1.92% |
1 Year | -17.66% |
3 Years | 107.24% |
5 Years | 263.15% |
Fredun Pharma News & Analysis
Fredun Pharma Share Recommendations
No Recommendations details available for this stock.
Check out other stock recos.
Fredun Pharma Financials
Income (P&L)
Balance Sheet
Cash Flow
Ratios
Insights
Quarterly Topline Performance
Company witnessed QoQ revenue decline of 33.23%, which is lowest in the last 3 years. (Source: Standalone Financials)Employee & Interest Expense
Company has spent 3.91% of its operating revenues towards interest expenses and 3.58% towards employee cost in the year ending Mar 31, 2024. (Source: Standalone Financials)
Quarterly | Annual Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Total Income 78.81 118.03 87.01 81.99 62.05 Total Income Growth (%) -33.23 35.66 6.13 32.14 -22.25 Total Expenses 69.38 107.82 77.48 73.32 55.35 Total Expenses Growth (%) -35.65 39.17 5.68 32.45 -18.89 EBIT 9.43 10.21 9.53 8.67 6.69 EBIT Growth (%) -7.63 7.13 9.94 29.53 -42.11 Profit after Tax (PAT) 4.13 5.06 4.22 3.94 2.40 PAT Growth (%) -18.42 19.87 7.29 63.89 -38.28 EBIT Margin (%) 11.97 8.65 10.95 10.57 10.79 Net Profit Margin (%) 5.24 4.29 4.85 4.80 3.87 Basic EPS (₹) 8.79 10.77 8.99 8.40 5.24 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Assets 307.60 257.28 186.99 161.62 133.16 Total Assets Growth (%) 19.56 37.59 15.70 21.37 26.93 Total Liabilities 186.13 160.90 118.93 118.55 91.84 Total Liabilities Growth (%) 15.68 35.29 0.32 29.08 39.32 Total Equity 121.47 96.38 68.06 43.07 41.32 Total Equity Growth (%) 26.03 41.61 58.02 4.24 5.98 Current Ratio (x) 1.47 2.04 2.07 1.50 1.30 Total Debt to Equity (x) 0.87 0.90 0.78 0.92 0.84 Contingent Liabilities 0.00 - - - - All figures in Rs Cr, unless mentioned otherwise
Insights
Decrease in Cash from Investing
Company has used Rs 7.64 cr for investing activities which is an YoY decrease of 18.77%. (Source: Standalone Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Cash flow from Operating Activities -0.44 -14.41 -2.38 0.17 -10.61 Net Cash used in Investing Activities -7.64 -9.40 -4.13 -1.39 -1.49 Net Cash flow from Financing Activities 5.99 25.18 7.47 -0.71 13.70 Net Cash Flow -2.08 1.36 0.96 -1.93 1.59 Closing Cash & Cash Equivalent 1.07 3.44 2.09 1.13 3.06 Closing Cash & Cash Equivalent Growth (%) -68.80 64.72 84.85 -63.12 108.56 Total Debt/ CFO (x) -240.51 -6.01 -22.17 233.27 -3.29 All figures in Rs Cr, unless mentioned otherwise
Insights
ROE Outperforming 5 Year Average
Company delivered ROE of 12.86% in year ending Mar 31, 2024 outperforming its 5 year avg. of 9.91%. (Source: Standalone Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Return on Equity (%) 12.86 11.21 9.30 4.67 4.60 Return on Capital Employed (%) 26.36 17.72 11.71 11.35 12.47 Return on Assets (%) 5.07 4.20 3.38 1.24 1.42 Interest Coverage Ratio (x) 2.85 3.19 3.30 2.53 1.99 Asset Turnover Ratio (x) 1.24 1.24 1.29 82.84 84.68 Price to Earnings (x) 21.60 32.68 64.10 92.59 24.45 Price to Book (x) 2.77 3.66 5.96 4.29 1.13 EV/EBITDA (x) 11.34 14.71 29.59 21.21 8.92 EBITDA Margin (%) 11.14 10.77 6.87 7.86 7.79
Fredun Pharma Peer Comparison
Fredun Pharma Stock Performance
Ratio Performance
Insights
Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of 107.24% as compared to Nifty Smallcap 100 which gave a return of 91.39%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated 107.24% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)
Choose from Peers
Choose from Stocks
- 1D
- 1W
- 1M
- 3M
- 6M
- 1Y
- 5Y
Loading...Insights
Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of 109.03% as compared to Nifty Smallcap 100 which gave a return of 92.43%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated 109.03% return as compared to Nifty Pharma which gave investors 64.81% return over 3 year time period. (as of last trading session)
See All Parameters
MF Ownership
MF Ownership details are not available.
Corporate Actions
Fredun Pharma Board Meeting/AGM
Fredun Pharma Dividends
- Others
Meeting Date Announced on Purpose Details Jul 29, 2024 Jul 22, 2024 Board Meeting Quarterly Results May 07, 2024 Apr 24, 2024 Board Meeting Audited Results & Final Dividend Feb 14, 2024 Feb 05, 2024 Board Meeting Quarterly Results Jan 18, 2024 Dec 26, 2023 AGM E.G.M. Dec 16, 2023 Dec 08, 2023 Board Meeting Others Type Dividend Dividend per Share Ex-Dividend Date Announced on Final 7% 0.7 Sep 22, 2023 May 25, 2023 Final 7% 0.7 Sep 16, 2021 Jun 29, 2021 Final 6% 0.66 Sep 18, 2020 Jul 29, 2020 Final 7% 0.7 - May 08, 2024 Final 7% 0.7 - May 16, 2022 No other corporate actions details are available.
About Fredun Pharma
Fredun Pharmaceuticals Ltd., incorporated in the year 1987, is a Small Cap company (having a market cap of Rs 370.06 Crore) operating in Pharmaceuticals sector. Fredun Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2023. Show More
Executives
Auditors
- DN
Daulat N Medhora
Chairman & Jt. M. DFMFredun Medhora
Managing Director & CFONMNariman Medhora
Non Executive DirectorARAspi Raimalwala
Ind. Non-Executive DirectorShow More - Savla & Associates
Industry
Key Indices Listed on
-
Address
URMI ESTATE,11th Floor,Ganpatrao Kadam Marg,Mumbai, Maharashtra - 400013
More Details
Trending in Markets
Fredun Pharma Quick Links
Equity Quick Links
More from Markets
IPOStock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.